The battle begins

Earlier I mentioned that Facet had rejected Biogen's buyout offer. Well, it seems that Biogen won't take no for an answer. Biogen apparently wants complete control of Facet badly enough that it is willing to buy out a majority of shares and then take over the board in a sort of deathmatch (as best as I can tell). Facet isn't biting, so it looks like a showdown is on the horizon. Even though Facet has held strong so far, I think Biogen could and should win out here.

Read the Facet release

And the Biogen Release

and an outside source on the whole situation

Yesterday, I reported the looming disaster for Addex after they pulled the plug on their lead drug candidate. Well, today the dust settled and it settled hard (expectedly) on the stock of the drugmaker...to the tune of a 75% loss. Addex still has a promising pipeline, so now could be a good time to hop on board...

Have a look at the Reuter's story for more


Finally, GSK has been on the warpath lately and now you can add Nanobio to the list of new partnerships with the British pharma giant. This partnership will be centered around the further development of Nanobio's new cold sore therapy. As per the usual, the agreement also contains incentives for Nanobio upon completion of various development/commercialization milestones. Don't expect GSK to stop anytime soon, it's a known fact that they are on the hunt for new deals...

Read the story in http://www.fiercebiotech.com/press-releases/gsk-and-nanobio-announce-licensing-agreement